v3.26.1
Stockholders Equity (Details Narrative)
 3 Months Ended
Sep. 17, 2021
USD ($)
integer
$ / shares
shares
Mar. 31, 2026
USD ($)
$ / shares
shares
Mar. 31, 2025
USD ($)
shares
Dec. 31, 2025
$ / shares
May 07, 2024
USD ($)
$ / shares
Referral agreement term five years        
Common stock, par value | $ / shares   $ 0.001   $ 0.001  
Gross proceeds from sale | $   $ 0 $ 1,128,838    
Class of warrant or right, term seven year        
Class of warrant or right, granted in period (in shares) | shares 30,000 10,700      
Exercise price of warrant (in usd per share) | $ / shares $ 7.20        
Conversion price per share | $ / shares   $ 3.10      
Number of tranches | integer 2        
Warrants outstanding (in shares) | $ $ 149,551 $ 19,300      
Warrants outstanding, term seven-year        
Common Shares Reserved for Conversion of Convertible Securities | shares   806,000      
Convertible Debt Instrument Principal Amount | $   $ 2,500,000      
Measurement Input, Implied Volatility          
Warrants outstanding, measurement input 100.00%        
Measurement Input, Risk-free Yield          
Warrants outstanding, measurement input 1.17%        
Measurement Input, Share Price          
Warrants outstanding, stock price | $ / shares $ 7.10        
ATM Agreement [Member]          
Common stock, par value | $ / shares         $ 0.001
Aggregate offering price | $   $ 13,800,000     $ 15,000,000.0
Common stock, shares sold | shares     159,431    
Gross proceeds from sale | $     $ 1,200,000    
Warrants To Purchase [Member]          
Common stock were excluded from calculation of diluted earnings | shares   10,700